FACE MAKE-UP BODY

COOH
OPTIM HYAL ™
O
COOH COOH
O O
O HOH
H OR O
OR
HO HO OR
OR
n
R = CH3-CO- or H-

Sequence of acetylated glucuronic acids

Function:
Skin smoothing.
Definition:
Obtained by biofermentation,
OPTIM HYAL™ contains Glycokines™,
oligosaccharides of acetylated glucuronic
acids (18±6 glucuronic acids, acetylation
degree 9±1%) having a similar structure to
hyaluronic acid fragments.
Properties:
Smoothes out wrinkles.
Moisturises skin surface and depth.
Increases skin suppleness and resistance.
Characteristics:
By stimulating hyaluronic acid neosynthesis
and by sustaining its turnover,
OPTIM HYAL™ helps deliver optimal
moisturising and viscoelastic properties.
In addition, OPTIM HYAL™ increases
elastin synthesis.
Points of interest:
Hyaluronic acid half-life is less than one day.
The natural pace of renewal decreases
with age. OPTIM HYAL™ acts to restore
Sustaining
and maintain an optimal hyaluronic acid a young and optim
optimal
al
renewal.
INCI name:
hyaluronic
hyal uronic acid
Hydrolyzed Yeast Extract - renewal
Cetyl Hydroxyethylcellulose -
Polyglucuronic Acid - Lecithin
Applications:
All skin care products for face,
eye contour and body.
before after 1 month
Formulation:
Water soluble.
Incorporate in the emulsion or gel between
25 and 80°C for 2 hours maximum.
Recommended use level:
3%
Patents:
FR 2 939 799 - WO 2010/067327 -
EP 2 367 852 - US 2015/0196475

www.sederma.com
E-mail: sederma@sederma.fr
Copyright© 2018 Sederma.
Significant decrease in wrinkle quantity
All rights reserved.
Part of Croda International Plc.
by 46% up to 96% after just 1 month
 CLAIM SUBSTANTIATION 10-2014

In vitro and ex vivo tests

EXTRACELLULAR MATRIX RENEWAL

Optimal and sustained hyaluronic acid neosynthesis Elastin synthesis
Hyaluronic acid production: Improvement of visco-elastic properties:
• On human keratinocytes (OPTIM HYAL™ eq. 3%) ....................+40%, p<0.01 • On human fibroblasts (OPTIM HYAL™ eq. 3%) ......................+359%, p<0.01
• On human keratinocytes (OPTIM HYAL™ eq. 5%) ....................+85%, p<0.01 • On human fibroblasts (OPTIM HYAL™ eq. 5%) ......................+552%, p<0.01
• On human fibroblasts (OPTIM HYAL™ eq. 5%) ........................+35%, p<0.01
Hyaluronic acid receptor CD44 expression: • On skin explants under accelerated ageing conditions
• On skin explants under accelerated ageing conditions (OPTIM HYAL™ 1.5% in a cream)...........................................+18%, p<0.04
(OPTIM HYAL™ 1.5% in a cream)...........................................+55%, p<0.02
OPTIM HYAL™ demonstrated a strong stimulating power on the
synthesis of elastin.

CD44 By stimulating CD44, a cell receptor involved in hyaluronic acid

red staining anchoring and turnover, and HAS-2 expression, OPTIM HYAL™
Control OPTIM HYAL™ 1.5% generates an efficient cutaneous water network and sustains the self-
renewal of hyaluronic acid.

Hyaluronan synthase-2 expression:

• On human fibroblasts (OPTIM HYAL™ eq. 3%) .....................+90.5%, p<0.01

In vivo tests - Instrumental evaluation

26 female volunteers, mean age 38, with dry skin and wrinkles, applied twice daily for 2 months a cream containing OPTIM HYAL™ 3% against placebo.
Single blind studies. Measurements after 1 month and 2 months. The results at 2 months are not presented here and are available on request.

MOISTURE SMOOTHNESS

• Superficial hydration (Corneometer®).................... +24% vs placebo, p<0.01 Main wrinkles (SILFLO™ profilometry)
• Depth ............................................................. -12.5%, p<0.01 up to -52%
• In-depth hydration (MoistureMeter™) .................... +12% vs placebo, p<0.01 • Density.............................................................. -46%, p<0.01 up to -96%
No significant placebo effect
In just 1 month, OPTIM HYAL™ moisturises both in depth and on the surface.
With OPTIM HYAL™, average density and depth of the main wrinkles are
significantly reduced.
SUPPLENESS

Skin visco-elastic properties (Aeroflexmeter®)

• Resistance ........................................................ +12% (p<0.05 vs placebo)
• Firmness ............................................................. +9% (p<0.05 vs placebo)
• Density.............................................................. +14% (p<0.01 vs placebo)

With OPTIM HYAL™, the skin becomes supple and resistant.

SELF-EVALUATION (after 3 weeks, n=104) T0 T1 month

SENSORY EVALUATION at Eurofins®

Micro-depressionary network (SILFLO™ profilometry)
Well-being during application agree
• Area occupied by wrinkles (50 -100 µm) .......... -22.5%, p<0.01 up to -58%
Moisturising effect
• Roughness ........................................................ -14%, p<0.01 up to -43%
disagree
• Smoothing ....................................................... +22%, p<0.01 up to +64%
Skin more elastic
No significant placebo effect
Skin less dry
Skin more comfortable After just one month, OPTIM HYAL™ significantly smoothes the
Skin nourishing effect cutaneous micro-depressionary network.
0 20 40 60 80 100

In only one month, OPTIM HYAL™ smoothes out wrinkles, moisturises, and makes the skin more supple and resistant.

Non-warranty: The information in this publication is believed to be accurate and is given in good faith, but no representation or warranty as to its completeness or accuracy
is made. Suggestions for uses or applications are only opinions. Users are responsible for determining the suitability of these products for their own particular purpose. No
representation or warranty, expressed or implied, is made with respect to information or products including, without limitation, warranties of merchantability, fitness for a
29 rue du Chemin Vert particular purpose, non-infringement of any third party patent or other intellectual property rights including, without limit, copyright, trademark and designs. Any trademarks
78612 Le Perray-en-Yvelines cedex France identified herein, unless otherwise noted, are trademarks of the Croda group of companies. ©2018 Sederma 02/18 PCS PO 001 V1 EN
Tel. : +33 (0)1 34 84 10 10 Reproduction of all or part of this document without the express prior written consent of Sederma is strictly prohibited.